{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=2", "query": { "condition": "Antineoplastic Agents", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T12:04:50.360Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03081858", "title": "Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer Cell Transitional", "Non-Muscle Invasive Bladder Cancer", "Bladder Cancer", "Urinary Bladder", "Transitional Cell Carcinoma of the Bladder", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Urogenital Neoplasms", "Urinary Bladder Diseases", "Urologic Diseases" ], "interventions": [ { "name": "TSD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lipac Oncology LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2018-05-17", "completion_date": "2021-08-05", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 5, "location_summary": "Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hanover", "state": "Maryland" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03081858" }, { "nct_id": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for Atezolizumab", "type": "DRUG" }, { "name": "Placebo for Ipatasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2019-11-25", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 31, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177108" }, { "nct_id": "NCT01191775", "title": "A Study of PNT2258 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Lymphoma", "Prostate Cancer", "Melanoma" ], "interventions": [ { "name": "PNT2258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2010-08", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191775" }, { "nct_id": "NCT00421811", "title": "A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "ADH-1", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adherex Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2007-04", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2010-12-28", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 7, "location_summary": "Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00421811" }, { "nct_id": "NCT04630756", "title": "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Haematological Malignancies" ], "interventions": [ { "name": "AZD4573", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 40, "start_date": "2021-02-17", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 4, "location_summary": "Duarte, California • La Jolla, California • Houston, Texas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630756" }, { "nct_id": "NCT03219333", "title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2017-10-08", "completion_date": "2023-07-28", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 54, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219333" }, { "nct_id": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer; HER2-positive; Metastatic" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1157, "start_date": "2021-04-26", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 30, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04784715" }, { "nct_id": "NCT05775159", "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2023-04-24", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Costa Mesa, California • Los Angeles, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775159" }, { "nct_id": "NCT06130553", "title": "A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors That Are MTAP Deficient" ], "interventions": [ { "name": "AZD3470", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2024-01-18", "completion_date": "2028-12-04", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 8, "location_summary": "San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06130553" }, { "nct_id": "NCT07109219", "title": "Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia (B-ALL)" ], "interventions": [ { "name": "AZD4512 monotherapy", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 83, "start_date": "2025-11-12", "completion_date": "2028-07-03", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-10T12:04:50.360Z", "location_count": 6, "location_summary": "Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Franklin", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07109219" } ] }